Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Simeprevir + Flat Dose Ribavirin in Elderly HCV Cirrhosis
NCT02702739Phase 4Completed
- Sponsor
- San Camillo-Forlanini
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir, simeprevir and ribavirin in hepatitis C (HCV) (2 arms), sponsored by San Camillo-Forlanini. Primary endpoint: Sustained Virological Response week 12. Started Jan 2015; status: completed.
02
Drugs
sofosbuvirsimeprevirribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02702739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702739.